BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33692962)

  • 1. Case Report:
    Wen Z; Xiong D; Zhang S; Liu J; Li B; Li R; Zhang H
    Front Oncol; 2021; 11():645370. PubMed ID: 33692962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.
    Yun KM; Bazhenova LA
    Cancer Manag Res; 2022; 14():843-850. PubMed ID: 35250311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
    Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
    Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.
    Passaro A; Lazzari C; Karachaliou N; Spitaleri G; Pochesci A; Catania C; Rosell R; de Marinis F
    Onco Targets Ther; 2016; 9():6361-6376. PubMed ID: 27799783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of
    Makuuchi Y; Hayashi H; Haratani K; Tanizaki J; Tanaka K; Takeda M; Sakai K; Shimizu S; Ito A; Nishio K; Nakagawa K
    Oncotarget; 2018 May; 9(33):23315-23319. PubMed ID: 29796191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
    Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
    Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors.
    Singh A; Chen H
    Cancer Manag Res; 2020; 12():6615-6628. PubMed ID: 32821158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
    Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
    Front Oncol; 2022; 12():761558. PubMed ID: 35237506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
    Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
    Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
    Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
    Wang W; Sun X; Hui Z
    Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report.
    Feng C; Zhou R; Liu F; Wang T; Liu S; Shao Y
    Front Oncol; 2021; 11():700341. PubMed ID: 34490099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.
    Karachaliou N; Fernandez Bruno M; Bracht JWP; Rosell R
    Onco Targets Ther; 2019; 12():4567-4575. PubMed ID: 31354290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
    Beardslee T; Lawson J
    J Adv Pract Oncol; 2018; 9(1):94-101. PubMed ID: 30564472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
    Gristina V; La Mantia M; Iacono F; Galvano A; Russo A; Bazan V
    Pharmaceuticals (Basel); 2020 Dec; 13(12):. PubMed ID: 33352844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.